DOCSLIB.ORG

Cytokines: from Basic Mechanisms of Control to New Therapeutics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cytokines: from Basic Mechanisms of Control to New Therapeutics This is a free sample of content from Cytokines: From Basic Mechanisms of Control to New Therapeutics. Click here for more information on how to buy the book. Index A Cryopyrin-associated periodic syndromes (CAPS), AKT 262–263 g chain family cytokine signaling, 9 CTCL. See Cutaneous T-cell lymphoma T-cell development role, 279 Cutaneous T-cell lymphoma (CTCL), interleukin-15 role, AMPs. See Antimicrobial peptides 448 Antimicrobial peptides (AMPs), 456 Cytokine release syndrome (CRS), interleukin-6 therapeutic Arid5a, 94 targeting, 93, 94 Atopic dermatitis Cytokine studies interleukin-17 studies, 130 agonist development, 458–459 interleukin-22 therapeutic targeting, 169 alarmins, 456–457 antagonist development, 459–460 assay development, 457 B definition, 455–456 B cell historical perspective, 456 g chain family cytokine function, 16–18 mimics, 457 interferon-g in activation, 226–227 mutation studies, 458 tumor necrosis factor in development and function, 105 signaling studies, 457–458 BCL11B, 280–281 b Common family cytokines. See also specific cytokines cancer studies, 46 D functions, 43–44 Daclizumab, 21 nervous system function, 46–47 DC. See Dendritic cell overview, 40–43 Dendritic cell (DC) receptors classical dendritic cells activation, 48–49, 51 cDC1 development and function, 397–398 assembly, 48 cDC2 development and function, 398–399 assembly, 48–51 GM-DCs, 403–404 interactions with other receptors, 47–48 human cell features, 401–402 proximal activation of signaling, 52–53 identification sepsis and inflammation studies, 44–45 mouse bone marrow, 396–397 therapy, 41–42, 53–56 surface markers for in vivo identification, 403 BLIMP1, 15 maturation, 404–406 Briakinumab, 151 Mo-DCs, 403 g chain family cytokine function, 19 C interferon-g in activation, 226 Candida albicans, interleukin-17 studies, 129 long noncoding RNA regulation of differentiation, CAPS. See Cryopyrin-associated periodic syndromes 297–298 Castleman disease, toclizumab therapy, 89 plasmacytoid dendritic cells CD. See Crohn’s disease development and function, 399–400 Ciliary neurotrophic factor (CNTF) human cell features, 402 overview, 72–73 subsets, 395 mutations and disease, 76 Diabetes type 1, g chain family cytokine studies, 20–21 trans-signaling, 75 Diabetic foot ulcer (DFU), interleukin-20 family member CISH, 317–318 therapy, 174–175 CNTF. See Ciliary neurotrophic factor Crohn’s disease (CD) g chain family cytokine studies, 20 E interleukin-10 studies, 159, 161–162 Ectodysplasin, 104 interleukin-22 therapy, 170–172 EPO. See Erythropoietin CRS. See Cytokine release syndrome Erythropoietin (EPO), receptor, 47–48 463 © 2018 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Cytokines: From Basic Mechanisms of Control to New Therapeutics. Click here for more information on how to buy the book. Index F IFN-a. See Interferon-a Familial Mediterranean fever (FMF), 263–264 IFN-g. See Interferon-g FGK 4.5, 444 IL-1. See Interleukin-1 FMF. See Familial Mediterranean fever IL-2. See Interleukin-2 Follicular lymphoma, interferon-a therapy, 437 IL-3. See Interleukin-3 FOXP3, 11, 332 IL-4. See Interleukin-4 IL-5. See Interleukin-5 G IL-6. See Interleukin-6 g Chain family cytokines. See also specific cytokines IL-7. See Interleukin-7 autoimmune disease role, 19–22 IL-9. See Interleukin-9 B-cell function, 16–18 IL-10. See Interleukin-10 gene expression mediation, 9–10 IL-11. See Interleukin-11 natural killer cell function, 18–19 IL-12. See Interleukin-12 overview, 1–5 IL-13. See Interleukin-13 receptors, 5–7 IL-15. See Interleukin-15 signaling, 7–9 IL-17. See Interleukin-17 structure, 2 IL-19. See Interleukin-19 T-cell function IL-20. See Interleukin-20 CD8þ T-cell development and differentiation, 16 IL-21. See Interleukin-21 development, 10–11 IL-22. See Interleukin-22 helper T-cell differentiation, 12–16 IL-23. See Interleukin-23 Tregs, 11–12 IL-24. See Interleukin-24 therapy, 22–25 IL-26. See Interleukin-26 GATA3 IL-28. See Interleukin-28 helper T cells IL-29. See Interleukin-29 differentiation role, 330–332 IL-33. See Interleukin-33 expression by noncanonical Th cell subtypes, IL-37. See Interleukin-37 332–333 ILC. See Innate lymphoid cell T-cell development role, 273–274, 277–280 Inflammation GCA. See Giant cell arteritis autoinflammatory disease. See Interleukin-1 Giant cell arteritis (GCA), toclizumab therapy, 92 b common family cytokine studies, 44–45 GM-CSF. See Granulocyte macrophage colony-stimulating granulocyte macrophage colony-stimulating factor factor role, 45 Graft-versus-host disease (GVHD), interleukin-22 interleukin-17 studies protective effects, 173–174 IL-17B, 131 Granulocyte macrophage colony-stimulating factor IL-17C, 131–132 (GM-CSF) IL-17D, 132 cancer immunotherapy, 439–440 IL-17E, 132 cancer studies, 46 tumor microenvironment, 414 functional overview, 43–44 tumor necrosis factor role, 103 nervous system function, 46–47 Innate lymphoid cell (ILC) receptor, 48–53 cytokine regulation sepsis and inflammation role, 45 group 1 cells, 382–383 therapeutic targeting, 53–55 group 2 cells, 383–385 GVHD. See Graft-versus-host disease group 3 cells, 385–387 interferon, 382–383 H interleukin-1, 387 HEB, T-cell development role, 280–281 interleukin-2, 381–382, 386 Hepatitis interleukin-4, 384–385 interferon-g therapy, 176 interleukin-5, 384, 389 interleukin-22 protective effects, 173 interleukin-7, 381–382, 386 HHV8. See Human herpes virus 8 interleukin-9, 384–385 Human herpes virus 8 (HHV8), interleukin-6, 73 interleukin-12, 388 interleukin-13, 384 interleukin-15, 381–382 I interleukin-17, 386–387 ID2, 400 interleukin-22, 386–387 IFN. See Interferon overview, 380–382 464 © 2018 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Cytokines: From Basic Mechanisms of Control to New Therapeutics. Click here for more information on how to buy the book. Index plasticity modulation, 387–388 interleukin-1 receptor antagonist deficiency, 265 tumor immunity, 388–389 intrinsic inflammasomopathies, 261–265 functional overview, 379–380 Majeed syndrome, 265 subsets, 380 mevalonate kinase deficiency, 266 Th cell relationship, 335–336 NLRC4-associated autoinflammatory Innate repair receptor (IRR), 47–48 diseases, 264 Interferon (IFN) NLRP12-associated autoinflammatory cancer studies, 197 disorder, 265 classes, 203–204, 206 overview, 261 classification, 436 pyogenic arthritis, pyoderma gangrenosum and innate lymphoid cell regulation, 382–383 acne syndrome, 265–266 long noncoding RNA regulation, 302–303 tumor necrosis factor receptor-associated periodic signaling, 196–197, 205 syndrome, 267 Interferon-a (IFN-a), cancer immunotherapy cellular sources, 240–241 follicular lymphoma, 437 expression regulation, 246 Kaposi sarcoma, 437 family members, 239, 255–256 melanoma, 437–438 immune regulation, 245–246 toxicity, 438 immune stimulation by inflammasome-dependent Interferon-g (IFN-g) cytokines, 260 antibodies, 457 inflammasome-dependent processing, 256–260 cancer immunoediting role innate lymphoid cell regulation, 387 elimination phase, 229–231 nuclear function, 248 equilibrium, 231–232 overview, 239–240 escape, 232–233 signaling regulation, 247–248 overview, 227–229 Interleukin-2 (IL-2) cancer studies, 176–177 autoimmune disease studies, 19–22 cellular sources, 220–221 cancer immunotherapy gene, 219 low-dose trials, 435–436 immune cell activation melanoma, 434–435 B cell, 226–227 overview, 433–434 dendritic cell, 226 renal cell carcinoma, 434–435 macrophage, 225–226 CD8þ T cell T cells function, 16 CD8þ T cells, 227 response to virus infection, 362–365, 370, 372 helper T cells, 227 functional overview, 2–3 Tregs, 227 helper T cell interferon regulatory factor regulation, 211–212 differentiation role, 12–13, 15–16 posttranslational modification, 220 fate determination, 329 receptor history of study, 1–2 activation, 224 innate lymphoid cell regulation, 381–382, 386 signaling pathway, 223, 225 natural killer cell function, 18 structure and function, 221–223 receptors, 1–2, 5–6 types, 175 regulatory T-cell regulation, 346–350 virus infection treatment, 175–176 therapy, 22–25 Interferon regulatory factor (IRF) Treg function, 11–12, 14–15 interferon-g regulation, 211–212 Interleukin-3 (IL-3) structure, 206 cancer studies, 46 type I interferon regulation functional overview, 44 cytosolic DNA recognition, 210–211 nervous system function, 46–47 cytosolic RNA recognition, 208–210 receptor, 48–53 Toll-like receptor signaling, 206–208 sepsis and inflammation role, 45 type III interferon regulation, 212 therapeutic targeting, 55 types, 206 Interleukin-4 (IL-4) Interleukin-1 (IL-1) B-cell function, 16–18 autoinflammatory disease studies functional overview, 3–4 cryopyrin-associated periodic syndromes, 262–263 innate lymphoid cell regulation, 384–385 extrinsic inflammasomopathies, 265–267 macrophage function, 19 familial Mediterranean fever, 263–264 natural killer cell function, 18–19 465 © 2018 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Cytokines: From Basic Mechanisms of Control to New Therapeutics. Click here for more information on how to buy the book. Index Interleukin-4 (IL-4) (Continued) cellular sources, 160 receptors, 6 family members, 157–159 T helper cell differentiation role, 12–14, 329 receptors, 158–159 therapy, 25 structure, 158 Interleukin-5 (IL-5) systemic lupus erythematosus therapeutic targeting, 163 functional overview, 44 therapy innate lymphoid cell regulation, 384, 389 Crohn’s disease, 159, 161–162 nervous system function, 46–47 mechanism
Load more

Recommended publications
  • Interleukin 28 Is a Potential Therapeutic Target for Sepsis
    Clinical Immunology 205 (2019) 29–34 Contents lists available at ScienceDirect Clinical Immunology journal homepage: www.elsevier.com/locate/yclim Interleukin 28 is a potential therapeutic target for sepsis T ⁎ Qin Luoa,b, Yi Liuc, Shuang Liub, Yibing Yinb, Banglao Xud, Ju Caoa, a Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China b Key Laboratory of Diagnostic Medicine designated by the Ministry of Education, Chongqing Medical University, Chongqing, China c Department of Intensive Care Unit, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China d Department of Laboratory Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China ARTICLE INFO ABSTRACT Keywords: Identification of new therapeutic targets for the treatment of sepsis is imperative. We report here that cytokine Interleukin-28 IL-28 (IFN-λ) levels were elevated in clinical and experimental sepsis. Neutralization of IL-28 protected mice Sepsis from lethal sepsis induced by cecal ligation and puncture (CLP), which was associated with improved bacterial Infection clearance and enhanced neutrophil infiltration. Conversely, administration of recombinant IL-28 aggravated Immunity mortality, facilitated bacterial dissimilation and limited neutrophil recruitment, in the model of sepsis induced Neutrophil by CLP. This study defines IL-28 as a detrimental mediator during sepsis and identifies a potential therapeutic target for the immune therapy in sepsis. 1. Introduction immunopathology of sepsis is still poorly understood. To address this issue, we examined the potential role of IL-28 in the Each year, about 31.5 million individuals develop sepsis, and up to progression of sepsis.
    [Show full text]
  • Mechanism of Action Through an IFN Type I-Independent Responses To
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 is online at: average * The Journal of Immunology , 12 of which you can access for free at: 2012; 188:3088-3098; Prepublished online 20 from submission to initial decision 4 weeks from acceptance to publication February 2012; doi: 10.4049/jimmunol.1101764 http://www.jimmunol.org/content/188/7/3088 MF59 and Pam3CSK4 Boost Adaptive Responses to Influenza Subunit Vaccine through an IFN Type I-Independent Mechanism of Action Elena Caproni, Elaine Tritto, Mario Cortese, Alessandro Muzzi, Flaviana Mosca, Elisabetta Monaci, Barbara Baudner, Anja Seubert and Ennio De Gregorio J Immunol cites 33 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription http://www.jimmunol.org/content/suppl/2012/02/21/jimmunol.110176 4.DC1 This article http://www.jimmunol.org/content/188/7/3088.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767
    [Show full text]
  • The Role of Il-29 and Il-28B in the Innate Immune Response
    THE ROLE OF IL-29 AND IL-28B IN THE INNATE IMMUNE RESPONSE Megumi A. Williamson A thesis submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Master of Science in the Department of Periodontology, School of Dentistry Chapel Hill 2018 Approved by: Thiago Morelli Thiago Morelli Julie Marchesan Steven Offenbacher Antonio Amelio ©2018 Megumi A. Williamson ALL RIGHTS RESERVED ii ABSTRACT Megumi A. Williamson: The Role of IL-29 and IL-28B in the Innate Immune Response (Under the direction of Thiago Morelli, Julie Marchesan, Steven Offenbacher, and Antonio Amelio) Aims: Chronic periodontitis (CP) is an inflammatory disease induced by dysbiotic biofilm in a susceptible host, resulting in progressive attachment loss, and subsequent alveolar bone loss. Recent genome-wide association studies (GWAS) and genome-wide gene centric analysis on periodontal complex traits (PCTs) identified possible associations of IL-29 and IL- 28B with periodontal diseases. However, the underlying mechanisms for how these genes contribute to the pathogenesis of periodontitis are largely unknown. The aims of the present study were to explore the role of IL-29 and IL-28B and their gene polymorphisms in the innate immune response by dendritic cells. Materials and methods: To explore the effect of IL-29 on the cytokine production in response to TLR4 stimulation, the IL-29 gene was knocked-down in THP-1 cells using IL-29 shRNA lentiviral particles. Pro- and anti-inflammatory cytokine levels were measured with Luminex® multiplex assay. To assess the effect of genetic variations in IL- 29 and IL-28B, whole blood samples from fifteen subjects (6 subjects with major allele for both IL-29 and IL-28B, 5 subjects for major allele in IL-29 and minor allele in IL-28B, and 4 subjects with minor alleles for both genes) were collected and CD14+/CD16lo PBMCs were isolated to generate DCs.
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]
  • Human Cytokine Response Profiles
    Comprehensive Understanding of the Human Cytokine Response Profiles A. Background The current project aims to collect datasets profiling gene expression patterns of human cytokine treatment response from the NCBI GEO and EBI ArrayExpress databases. The Framework for Data Curation already hosted a list of candidate datasets. You will read the study design and sample annotations to select the relevant datasets and label the sample conditions to enable automatic analysis. If you want to build a new data collection project for your topic of interest instead of working on our existing cytokine project, please read section D. We will explain the cytokine project’s configurations to give you an example on creating your curation task. A.1. Cytokine Cytokines are a broad category of small proteins mediating cell signaling. Many cell types can release cytokines and receive cytokines from other producers through receptors on the cell surface. Despite some overlap in the literature terminology, we exclude chemokines, hormones, or growth factors, which are also essential cell signaling molecules. Meanwhile, we count two cytokines in the same family as the same if they share the same receptors. In this project, we will focus on the following families and use the member symbols as standard names (Table 1). Family Members (use these symbols as standard cytokine names) Colony-stimulating factor GCSF, GMCSF, MCSF Interferon IFNA, IFNB, IFNG Interleukin IL1, IL1RA, IL2, IL3, IL4, IL5, IL6, IL7, IL9, IL10, IL11, IL12, IL13, IL15, IL16, IL17, IL18, IL19, IL20, IL21, IL22, IL23, IL24, IL25, IL26, IL27, IL28, IL29, IL30, IL31, IL32, IL33, IL34, IL35, IL36, IL36RA, IL37, TSLP, LIF, OSM Tumor necrosis factor TNFA, LTA, LTB, CD40L, FASL, CD27L, CD30L, 41BBL, TRAIL, OPGL, APRIL, LIGHT, TWEAK, BAFF Unassigned TGFB, MIF Table 1.
    [Show full text]
  • Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies
    viruses Review Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies Laura A. Novotny 1 , John Grayson Evans 1, Lishan Su 2, Haitao Guo 3 and Eric G. Meissner 1,4,* 1 Division of Infectious Diseases, Medical University of South Carolina, Charleston, SC 29525, USA; [email protected] (L.A.N.); [email protected] (J.G.E.) 2 Division of Virology, Pathogenesis, and Cancer, Institute of Human Virology, Departments of Pharmacology, Microbiology, and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; [email protected] 3 Department of Microbiology and Molecular Genetics, Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; [email protected] 4 Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA * Correspondence: [email protected]; Tel.: +1-843-792-4541 Abstract: Hepatitis B virus (HBV) chronically infects over 250 million people worldwide and causes nearly 1 million deaths per year due to cirrhosis and liver cancer. Approved treatments for chronic infection include injectable type-I interferons and nucleos(t)ide reverse transcriptase inhibitors. A small minority of patients achieve seroclearance after treatment with type-I interferons, defined as sustained absence of detectable HBV DNA and surface antigen (HBsAg) antigenemia. However, type-I interferons cause significant side effects, are costly, must be administered for months, and most patients have viral rebound or non-response. Nucleos(t)ide reverse transcriptase inhibitors reduce HBV viral load and improve liver-related outcomes, but do not lower HBsAg levels or impart Citation: Novotny, L.A.; Evans, J.G.; seroclearance.
    [Show full text]
  • RT² Profiler PCR Array (384-Well Format) Human Inflammatory Response & Autoimmunity
    RT² Profiler PCR Array (384-Well Format) Human Inflammatory Response & Autoimmunity Cat. no. 330231 PAHS-3803ZE For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 7900HT (384-well block), Format E ViiA™ 7 (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (384-well block) Format G Description The Human Inflammatory Response & Autoimmunity RT² Profiler PCR Array profiles the expression of 370 key genes involved in immune response during autoimmunity and inflammation. It represents the expression of inflammatory cytokines, chemokines, and their receptors. It also contains genes related to the production and metabolism of cytokines. Genes involved in cytokine-cytokine receptor interactions are as well as thoroughly researched panels of genes involved in the acute-phase, inflammatory, and humoral immune responses. Using real-time PCR, you can easily and reliably analyze the expression of a focused panel of genes related to autoimmunity and inflammation with this array. For further details, consult the RT² Profiler PCR Array Handbook. Sample & Assay Technologies Shipping and storage RT² Profiler PCR Arrays in formats E and G are shipped at ambient temperature, on dry ice, or blue ice packs depending on destination and accompanying products. For long term storage, keep plates at –20°C. Note: Ensure that you have the correct RT² Profiler PCR Array format for your real-time cycler (see table above). Note: Open the package and store
    [Show full text]
  • 1 SUPPLEMENTAL DATA Figure S1. Poly I:C Induces IFN-Β Expression
    SUPPLEMENTAL DATA Figure S1. Poly I:C induces IFN-β expression and signaling. Fibroblasts were incubated in media with or without Poly I:C for 24 h. RNA was isolated and processed for microarray analysis. Genes showing >2-fold up- or down-regulation compared to control fibroblasts were analyzed using Ingenuity Pathway Analysis Software (Red color, up-regulation; Green color, down-regulation). The transcripts with known gene identifiers (HUGO gene symbols) were entered into the Ingenuity Pathways Knowledge Base IPA 4.0. Each gene identifier mapped in the Ingenuity Pathways Knowledge Base was termed as a focus gene, which was overlaid into a global molecular network established from the information in the Ingenuity Pathways Knowledge Base. Each network contained a maximum of 35 focus genes. 1 Figure S2. The overlap of genes regulated by Poly I:C and by IFN. Bioinformatics analysis was conducted to generate a list of 2003 genes showing >2 fold up or down- regulation in fibroblasts treated with Poly I:C for 24 h. The overlap of this gene set with the 117 skin gene IFN Core Signature comprised of datasets of skin cells stimulated by IFN (Wong et al, 2012) was generated using Microsoft Excel. 2 Symbol Description polyIC 24h IFN 24h CXCL10 chemokine (C-X-C motif) ligand 10 129 7.14 CCL5 chemokine (C-C motif) ligand 5 118 1.12 CCL5 chemokine (C-C motif) ligand 5 115 1.01 OASL 2'-5'-oligoadenylate synthetase-like 83.3 9.52 CCL8 chemokine (C-C motif) ligand 8 78.5 3.25 IDO1 indoleamine 2,3-dioxygenase 1 76.3 3.5 IFI27 interferon, alpha-inducible
    [Show full text]
  • Supplementary Information for Table of Contents
    Supplementary Information for Tracing the origin of a new organ by inferring the genetic basis of rumen evolution Table of contents Supplementary Notes Supplementary Figures Supplementary Tables References 1 1 Supplementary Notes 2 Part 1. Phylogeny relationship and sample collection 3 1.1 Construction of the phylogenetic tree 4 To present the evolutionary panorama of the multi-chambered stomach evolution in 5 Cetartiodactyla, we constructed a phylogenetic tree using four-fold degenerate sites 6 using single-copy orthologous genes from nine species (human, horse, camel, pig, 7 hippo, killer whale, lesser mouse-deer, roe deer, and sheep) as representatives of the 8 major taxonomy. A final maximum likelihood tree was generated using IQ-TREE 9 multicore (version 1.6.6.a)1 with the parameters “-bb 1000 -m TEST -o Human” (Fig. 10 S17). Note that one of the families in the Suina, the Tayassuidae, has one stomach 11 with three chambers. Although no genomes of species in the Tayassuidae are 12 available, we chose the peccary as the representative of Tayassuidae and present the 13 position of the peccary according to the results of mitochondrial genomes2. The 14 newick format of tree result is as follows: (((((LesserMouse- 15 deer:0.1383065387,(Roedeer:0.0549981637,Sheep:0.0511103239)100:0.0574393138) 16 100:0.0488086408,(Killerwhale:0.0631824323,Hippo:0.0758665489)100:0.00822769 17 45)100:0.0179186732,Pig:0.1394609521)100:0.0101113682,Camel:0.1196798498)10 18 0:0.0411710418,Horse:0.1192130573,Human:0.1795944986); 19 1.2 RNA-seq analysis 20 1.2.1 Collection and sources of samples for RNA-seq 21 We collected and sequenced a total of 323 tissue samples from 11 Texel ♂ × Kazakh 22 ♀ hybrid sheep (Ovis aries) in Yili city (Xinjiang, China) (210 sequenced and 123 23 used in another paper at our laboratory)3.
    [Show full text]
  • Flavone Effects on the Proteome and Transcriptome of Colonocytes in Vitro and in Vivo and Its Relevance for Cancer Prevention and Therapy
    TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl für Ernährungsphysiologie Flavone effects on the proteome and transcriptome of colonocytes in vitro and in vivo and its relevance for cancer prevention and therapy Isabel Winkelmann Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. D. Haller Prüfer der Dissertation: 1. Univ.-Prof. Dr. H. Daniel 2. Univ.-Prof. Dr. U. Wenzel (Justus-Liebig-Universität Giessen) 3. Prof. Dr. E.C.M. Mariman (Maastricht University, Niederlande) schriftliche Beurteilung Die Dissertation wurde am 24.08.2009 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 25.11.2009 angenommen. Die Forschung ist immer auf dem Wege, nie am Ziel. (Adolf Pichler) Table of contents 1. Introduction .......................................................................................................... 1 1.1. Cancer and carcinogenesis .................................................................................. 2 1.2. Colorectal Cancer ............................................................................................... 3 1.2.1. Hereditary forms of CRC ........................................................................................ 4 1.2.2. Sporadic forms of CRC ..........................................................................................
    [Show full text]
  • Immune Cells in Spleen and Mucosa + CD127 Neg Production of IL-17 and IL-22 by CD3 TLR5 Signaling Stimulates the Innate
    Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 neg is online at: average * The Journal of Immunology , 23 of which you can access for free at: 2010; 185:1177-1185; Prepublished online 21 Immune Cells in Spleen and Mucosa from submission to initial decision + 4 weeks from acceptance to publication TLR5 Signaling Stimulates the Innate Production of IL-17 and IL-22 by CD3 CD127 Laurye Van Maele, Christophe Carnoy, Delphine Cayet, Pascal Songhet, Laure Dumoutier, Isabel Ferrero, Laure Janot, François Erard, Julie Bertout, Hélène Leger, Florent Sebbane, Arndt Benecke, Jean-Christophe Renauld, Wolf-Dietrich Hardt, Bernhard Ryffel and Jean-Claude Sirard June 2010; doi: 10.4049/jimmunol.1000115 http://www.jimmunol.org/content/185/2/1177 J Immunol cites 51 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/185/2/1177.full#ref-list-1 http://www.jimmunol.org/content/suppl/2010/06/21/jimmunol.100011 5.DC1 This article Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
    [Show full text]
  • Ncounter® Host Response Panel - Gene and Probe Details
    nCounter® Host Response Panel - Gene and Probe Details Gene Accession Synonyms Full Name Other targets or Isoform Information ACE NM 000789.2 DCP1;angiotensin I converting enzyme (peptidyl-dipeptidase A) 1;ACE1,CD143;peptidyl-dipeptidase A angiotensin I converting enzyme ACKR2 NM 001296.5 CMKBR9,CCBP2;chemokine binding protein 2;CCR10,D6,CCR9 atypical chemokine receptor 2 ACKR3 NM 020311.1 CMKOR1,CXCR7;chemokine orphan receptor 1,chemokine (C-X-C motif) receptor 7;RDC1,GPR159 atypical chemokine receptor 3 ACKR4 NM 016557.2 CCRL1;chemokine (C-C motif) receptor-like 1;CCR11,CCBP2,VSHK1,CCX-CKR,PPR1 atypical chemokine receptor 4 ACOX1 NM 001185039.1 acyl-Coenzyme A oxidase 1, palmitoyl,acyl-CoA oxidase 1, palmitoyl;PALMCOX;palmitoyl-CoA oxidase acyl-CoA oxidase 1 FACL2;fatty-acid-Coenzyme A ligase, long-chain 2;LACS2,LACS,ACS1,LACS1,FACL1;lignoceroyl-CoA synthase,long-chain fatty-acid- ACSL1 NM_001995.4 coenzyme A ligase 1 acyl-CoA synthetase long chain family member 1 ACSL3 NM 203372.1 FACL3;fatty-acid-Coenzyme A ligase, long-chain 3;ACS3,PRO2194 acyl-CoA synthetase long chain family member 3 FACL4,MRX63,MRX68;fatty-acid-Coenzyme A ligase, long-chain 4,mental retardation, X-linked 63,mental retardation, X-linked ACSL4 NM_004458.2 68;ACS4,LACS4;lignoceroyl-CoA synthase, long-chain fatty-acid-Coenzyme A ligase 4 acyl-CoA synthetase long chain family member 4 ACVR1 NM 001105.2 ACVRLK2;activin A receptor, type I;SKR1,ALK2,ACVR1A activin A receptor type 1 ADAR NM 001025107.1 IFI4,G1P1;interferon-induced protein 4;ADAR1 adenosine deaminase RNA
    [Show full text]